{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:08:44Z","timestamp":1792451324006,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bmcl.2023.129590","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T07:35:30Z","timestamp":1702366530000},"page":"129590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo"],"prefix":"10.1016","volume":"98","author":[{"given":"Sanfeng","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-8473","authenticated-orcid":false,"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-6918","authenticated-orcid":false,"given":"Yingxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-4596","authenticated-orcid":false,"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-5299","authenticated-orcid":false,"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129590_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2023.129590_b0010","doi-asserted-by":"crossref","unstructured":"R. Soutar, H. Lucraft, G. Jackson, A. Reece, J. Bird, E. Low, D. Samson, U.K.M.F. Working Group of the, H. British Committee for Standards in, H. British Society for, Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma, Clin Oncol (Royal College of Radiologists (Great Britain)), 16 (2004) 405-413.","DOI":"10.1016\/j.clon.2004.02.007"},{"key":"10.1016\/j.bmcl.2023.129590_b0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.bmcl.2023.129590_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e20023","article-title":"Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016","volume":"36","author":"Cowan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2023.129590_b0025","doi-asserted-by":"crossref","unstructured":"M. Attal, V. Lauwers-Cances, C. Hulin, X. Leleu, D. Caillot, M. Escoffre, B. Arnulf, M. Macro, K. Belhadj, L. Garderet, M. Roussel, C. Payen, C. Mathiot, J.P. Fermand, N. Meuleman, S. Rollet, M.E. Maglio, A.A. Zeytoonjian, E.A. Weller, N. Munshi, K.C. Anderson, P.G. Richardson, T. Facon, H. Avet-Loiseau, J.L. Harousseau, P. Moreau, I.F.M. Study, lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma, New Engl J Med. 376 (2017) 1311-1320.","DOI":"10.1056\/NEJMoa1611750"},{"key":"10.1016\/j.bmcl.2023.129590_b0030","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk multiple myeloma: definition and management","volume":"17","author":"Joseph","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bmcl.2023.129590_b0035","first-page":"29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States","volume":"24","author":"Carlson","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.bmcl.2023.129590_b0040","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/cbin.11402","article-title":"A review of the chemopreventative and chemotherapeutic properties of the phytochemicals berberine, resveratrol and curcumin, and their influence on cell death via the pathways of apoptosis and autophagy","volume":"44","author":"D'Arcy","year":"2020","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.bmcl.2023.129590_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-10-104","article-title":"Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmcl.2023.129590_b0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jmf.2012.2628","article-title":"8-Hydrocalamenene, derived from reynoutria elliptica, suppresses constitutive STAT3 activation, inhibiting proliferation and enhancing chemosensitization of human multiple myeloma cells","volume":"17","author":"Nam","year":"2014","journal-title":"J Med Food"},{"key":"10.1016\/j.bmcl.2023.129590_b0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ejmech.2019.07.041","article-title":"Targeting multiple myeloma with natural polyphenols","volume":"180","author":"Pojero","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129590_b0060","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/j.1349-7006.2008.00872.x","article-title":"Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK\/STAT pathway","volume":"99","author":"Sagawa","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmcl.2023.129590_b0065","doi-asserted-by":"crossref","first-page":"26718","DOI":"10.18632\/oncotarget.14957","article-title":"TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma","volume":"8","author":"Tao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2023.129590_b0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/0008-5472.CAN-18-3987","article-title":"A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2023.129590_b0075","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41375-023-01925-w","article-title":"Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma","volume":"37","author":"Xu","year":"2023","journal-title":"Leukemia"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23004687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23004687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T16:06:42Z","timestamp":1726848402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23004687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":15,"alternative-id":["S0960894X23004687"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129590","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129590"}}